key: cord-0964676-0utak8of authors: Wang, Huanyu; Jean, Sophonie; Wilson, Sarah A.; Lucyshyn, Jocelyn M.; McGrath, Sean; Wilson, Richard K.; Magrini, Vincent; Leber, Amy L. title: A deletion in the N gene of SARS-CoV-2 may reduce test sensitivity for detection of SARS-CoV-2 date: 2021-12-29 journal: Diagn Microbiol Infect Dis DOI: 10.1016/j.diagmicrobio.2021.115631 sha: b71346ca99e4b803ea8f6ec0f842a63ff710575f doc_id: 964676 cord_uid: 0utak8of One SARS-CoV-2-positive sample demonstrated impaired detection of the N1 target by RT-PCR using US CDC primer/probe sets. A three nucleotide deletion was discovered that overlaps the forward primer binding site. This finding underscores the importance of continued SARS-CoV-2 mutation surveillance and assessment of the impact on diagnostic test performance. One SARS-CoV-2-positive sample demonstrated impaired detection of the N1 target by RT-PCR using US CDC primer/probe 20 sets. A three nucleotide deletion was discovered that overlaps the forward primer binding site. This finding underscores the 21 importance of continued SARS-CoV-2 mutation surveillance and assessment of the impact on diagnostic test performance. 22 Keyword: SARS-CoV-2 NAAT, SARS-CoV-2 mutation 23 Funding: This research was partially funded by the Nationwide Foundation Pediatric Innovation Fund. 24 Nucleic acid amplification tests (NAAT) remain the mainstay for the laboratory diagnosis of the SARS-CoV-2 infection. The high 26 sensitivity and specificity of these tests rely on carefully designed primer/probe sets targeting the conserved regions of the viral 27 genome. One month after the first report of COVID-19, the viral genome was made available to the public [1] . Many primer/probe 28 sets were designed based on the original sequences (Wuhan-Hu-1, NC_045512.2) and soon adopted by clinical laboratories and 29 in vitro diagnostics manufacturers. As the pandemic continues, the virus continues to evolve. Changes in the viral genome, in 30 particular the spike gene, have been associated with increased transmissibility and virulence, reduced susceptibility to 31 convalescent or vaccinated sera, while changes in S gene and other regions of the genome, such as the N or E gene, have been 32 reported to adversely impact the performance of some NAATs resulting in reduced test sensitivity [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . and N2 assays were designed to specifically detect SARS-CoV-2 while N3 assay can recognize viruses within the subgenus 37 Sarbecovirus [13] . The N3 target was later dropped from the panel following reports of low specificity. Subsequently, many 38 commercial and lab-developed tests used the N1, N2 primer/probe sets to detect SARS-CoV-2. The clinical microbiology 39 laboratories at Nationwide Children's Hospital adopted the US CDC N1 and N2 primer/probe sets and fully validated and 40 implemented the testing for clinical use with FDA EUA granted in April 2020 (NCH EUA LDT). Here we report one incidence that 41 demonstrates poor N1 gene assay performance relative to the N2 assay. 42 In October 2021, a nasopharyngeal sample from a 2 year-old hospitalized female patient presenting to the emergency room with 43 pneumonia was submitted for routine diagnostic SARS-CoV-2 testing. The sample tested positive with the NCH EUA LDT, but test 44 results showed discrepant Ct profiles with a Ct value of 37.1 for the N1 assay and 17.1 for the N2 assays. Repeat testing 45 confirmed this finding. This sample was reported as positive for SARS-CoV-2. Additional testing results using the Xpert Xpress 46 SARS-CoV-2 assay (Cepheid, Sunnyvale, CA), BioFire FilmArray Respiratory Panel v2.1 (Salt Lake City, UT) and BD BioGX 47 SARS-CoV-2 assay (Franklin Lakes, NJ) are presented in Table 1 . This sample presented similar discrepant Ct profiles in the BD 48 BioGx SARS-CoV-2 assay which also utilizes US CDC primer/probe sets. The large Ct value difference between the N1 and N2 49 assays with the NCH EUA LDT prompted further investigation as mutation(s) in the primer and/or probe binding sites in the N 50 gene were suspected. The N gene of SARS-CoV-2 encodes the nucleocapsid protein, a major structural component of the virus, and is relatively well-65 conserved; it is the target of many diagnostic assays for COVID-19, including NAATs, antigen, and antibody-based tests. 66 Mutations in the N-gene that affect NAAT performance have been previously reported. Notably, a GGG-AAC mutation in the N 67 gene (28881-28883) overlaps the forward primer binding site of the Chinese CDC N assay ( Figure 1C ). This mutation was found 68 in a significant portion of SARS-CoV-2 sequences in GISAID and renders the inclusivity of this assay as low as 63.89% in a recent 69 analysis [14] . Single nucleotide polymorphisms C29200T, C29200A, C29197T and G29227T overlapping the US CDC N2 probe 70 or reverse primer have also been reported. They may be associated with the failure of amplification of the N gene by the Xpert 71 Xpress SARS-CoV-2 assay [3, 6, 10]. The impact of these SNPs on the performance of the US CDC N2 assay has yet to be 72 In testing over 50,000 samples since implementation, we have only detected this in one sample. To our knowledge, this is the first 74 report of a mutation in the N gene that affects US CDC N1 assay. This mutation will similarly impact diagnostic test performance 75 that utilizes the US CDC N1 primer/probe, exemplified by results from testing of our sample with the BD BioGX SARS-CoV-2 76 assay. Although the three-nucleotide deletion reported here has been identified twice previously from Germany, it is unlikely to 77 represent many of the circulating strains. Using a multi-target approach, mutations that affect one set of primer/probes will not 78 cause a false-negative result. Nevertheless, laboratories should be aware of the assay targets and their assays' primer/probe 79 binding sites and regularly monitor inclusivity against currently circulating strains. Our finding underscores the importance of 80 continuous SARS-CoV-2 mutation surveillance, regular assessment of diagnostic test performance as the virus continues 81 evolving, and including multiple targets in the assay to maintain maximal inclusivity. 82 We would like to thank the staff at the NCH Institution of Genomic Medicine for sequencing the specimen and Clinical 121 microbiology laboratories for their dedication during the COVID19 pandemic. 122 view illustrates forward (red arrows) and reverse (blue arrows) read alignments between genome coordinates NC_045512.2:28,272-29,500, 131 representing sequence coverage depth at each base position (gray bars above read alignments). A. The US CDC NAAT N1 assay illustrating the 132 nucleotide sequence, N gene protein translation, primer (black arrows), and probe binding (orange box) sites are the IGV tracks below the 133 sequence read track. A three-nucleotide deletion (r.28,898-28,300) results in an in-frame 9Q deletion localized to the N1-F primer binding site 134 (black box -3-) with a concomitant loss of sequence coverage (missing gray columns). B. An IGV snapshot of the US CDC NAAT N1 and N2 135 assays and the China CDC NAAT N assay. The N1 and N2 primers (black arrows) and probes (oranges boxes) flank the China CDC NAAT N 136 assay (primers are gray arrows, and the probe is the yellow box). C. The China CDC NAAT N assay illustrating the nucleotide sequence, N gene 137 protein translation, primer (gray arrows), and probe binding (yellow box) sites are the IGV tracks below the sequence read track. The reported 138 location of the GGG to AAC mutation at positions r.28,882-28,884 (adjacent to the black box and the 28,880 G>T substitution) impacts the 139 forward primer binding site 5' GGGGAACTTCTCCTGCTAGAAT and results in poor assay performance. 140 A Novel Coronavirus from Patients with Pneumonia in China A Recurrent Mutation at Position 26340 of SARS-CoV-2 Is Associated with Failure of the E Gene Quantitative Reverse 85 Transcription-PCR Utilized in a Commercial Dual-Target Diagnostic Assay A Novel Point Mutation in the N Gene of SARS-CoV-2 May Affect the Detection of the Virus by Reverse Transcription-87 Quantitative PCR Identification of Novel Mutations in the N Gene of SARS-CoV-2 That Adversely Affect the Detection of the Virus by 89 Reverse Transcription-Quantitative PCR. Microbiol Spectr Novel indel mutation in the N gene of SARS-CoV-2 clinical samples that were diagnosed positive in a commercial RT-PCR 91 assay SARS-CoV-2 N gene mutations impact detection by clinical molecular diagnostics: reports in two cities in the United 93 States Identification of a Polymorphism in the N Gene of SARS-CoV-2 That Adversely Impacts Detection by Reverse 95 Transcription-PCR SARS-CoV-2 N gene dropout and N gene Ct value shift as indicator for the presence of B.1.1.7 lineage in a 97 commercial multiplex PCR assay A deletion in the N gene may cause diagnostic escape in SARS-CoV-2 samples SARS-CoV-2 samples may escape detection because of a single point mutation in the N gene Multiple detection and spread of novel strains of the SARS-CoV-2 B.1.177 (B.1.177.75) lineage that test negative by a 102 commercially available nucleocapsid gene real-time RT-PCR Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion 104 H69-V70, France US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Deepening of In Silico Evaluation of SARS-CoV-2 Detection RT-qPCR Assays in the Context of New Variants Declarations of interest: none 110 Author contributions Study design, data curation and analysis, writing, reviewing and editing 112 Sophonie Jean: data analysis, reviewing and editing Genome library preparation, Illumina sequencing, data processing Genome library preparation, Illumina sequencing, data processing Genome profiling assay development, genome analysis development, data review, writing Genome profiling assay development, genome analysis development, data review, writing Genome profiling assay development, genome analysis development, data review, writing Study design, writing, reviewing and editing